Advances in Prognostic Methylation Biomarkers for Prostate Cancer

Advances in Prognostic Methylation Biomarkers for Prostate Cancer

There is a major clinical need for accurate biomarkers for prostate cancer prognosis, to better inform treatment strategies and disease monitoring. Current clinically recognised prognostic factors, including prostate-specific antigen (PSA) levels, lack sensitivity and specificity in distinguishing a...

Full description

Bibliographic Details
Main Authors: Dilys Lam, Susan Clark, Clare Stirzaker, Ruth Pidsley
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Cancers
Subjects:
DNA methylation
epigenetics
biomarkers
circulating DNA
cfDNA
prostate cancer
Online Access:https://www.mdpi.com/2072-6694/12/10/2993

Similar Items

Similar Items